Digestive Diseases and Sciences

, Volume 55, Issue 2, pp 415–420 | Cite as

Clinical Outcomes of Patients with Ulcerative Colitis and Co-existing Clostridium difficile Infection

  • Daniela Jodorkovsky
  • Yuki Young
  • Maria T. Abreu
Original Article


Background The incidence of Clostridium difficile infection is increasing in the United States. The aim of our investigation is to compare short-term and long-term outcomes of patients admitted with an ulcerative colitis (UC) flare and co-existent C. difficile infection to those of non-infected patients. Methods A historical cohort study was undertaken examining admissions at Mount Sinai Hospital between June 2004 and June 2005 using ICD-9 criteria for UC. Charts were abstracted for those patients for whom C. difficile testing was performed. Results Of 288 admissions, 99 charts met the inclusion criteria. Fifty-two patients were C. difficile-negative and 47 were positive. Demographic data and laboratory values upon admission did not differ between the two groups. Patients who were C. difficile-positive had significantly more UC-related hospitalizations and emergency room visits in the year following initial admission (58 visits vs. 27, P = 0.001 and eight visits vs. 1 visit (P = 0.012), respectively). One year following the index admission, C. difficile patients had significantly higher rates of colectomy compared to C. difficile-negative patients (44.6% vs. 25%, P = 0.04). Length of hospitalization (11.7 vs. 11 days), use of cyclosporine therapy during index admission (48% vs. 47% of patients), and percentage requiring colectomy at initial admission (23.4% vs. 13.5%) did not reach statistical significance. Conclusions Our data suggest that patients presenting with a UC flare who are infected with C. difficile have worse long-term clinical outcomes than those that are C. difficile-negative. C. difficile testing should be performed for all patients presenting with UC flare. Further studies are warranted to elucidate how infection can alter the natural history of UC.


Inflammatory bowel disease Clostridium difficile Ulcerative colitis 


  1. 1.
    Archibald L, Banerjee S, Jarvis W. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis. 2004;189:1585–1589. doi: 10.1086/383045.CrossRefPubMedGoogle Scholar
  2. 2.
    Greenfield C, Aguilar Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut. 1983;24(8):713–717. doi: 10.1136/gut.24.8.713.CrossRefPubMedGoogle Scholar
  3. 3.
    Meyer A, Nizar R, Loftus E, et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38(9):772–775. doi: 10.1097/01.mcg.0000139057.05297.d6.CrossRefPubMedGoogle Scholar
  4. 4.
    Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16(8):775–778. doi: 10.1097/01.meg.0000131040.38607.09.CrossRefPubMedGoogle Scholar
  5. 5.
    Kochhar R, Ayyagari A, Goenka MK, et al. Role of infectious agents in exacerbation of ulcerative colitis in India: a study of Clostridium difficile. J Clin Gastroenterol. 1993;16(1):26–30. doi: 10.1097/00004836-199301000-00008.CrossRefPubMedGoogle Scholar
  6. 6.
    Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80(4):693–696.PubMedGoogle Scholar
  7. 7.
    Weber P, Koch M, Heizmann WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol. 1992;14(4):302–308. doi: 10.1097/00004836-199206000-00008.CrossRefPubMedGoogle Scholar
  8. 8.
    Rodemann J, Dubberke E, Reske K, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):339–344. doi: 10.1016/j.cgh.2006.12.027.CrossRefPubMedGoogle Scholar
  9. 9.
    Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981;80(4):697–700.PubMedGoogle Scholar
  10. 10.
    LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980;1(8165):381–383. doi: 10.1016/S0140-6736(80)90939-3.CrossRefPubMedGoogle Scholar
  11. 11.
    Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhea: a role in inflammatory bowel disease? Lancet. 1980;1(8165):383–384. doi: 10.1016/S0140-6736(80)90940-X.CrossRefPubMedGoogle Scholar
  12. 12.
    Rüssmann H, Panthel K, Bader RC, et al. Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens. Eur J Clin Microbiol Infect Dis. 2007;26(2):115–119. doi: 10.1007/s10096-006-0251-7.CrossRefPubMedGoogle Scholar
  13. 13.
    Aldeen WE, Bingham M, Aiderzada A, et al. Comparison of the TOX A/B test to a cell culture cytotoxicity assay for the detection of Clostridium difficile in stools. Diagn Microbiol Infect Dis. 2000;36(4):211–213. doi: 10.1016/S0732-8893(00)00113-9.CrossRefPubMedGoogle Scholar
  14. 14.
    Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262. doi: 10.1056/NEJM199401273300406.CrossRefPubMedGoogle Scholar
  15. 15.
    Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium difficile in patients with Inflammatory Bowel Disease. Gut. 2007 [Epub ahead of print].Google Scholar
  16. 16.
    Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–351. doi: 10.1016/j.cgh.2006.12.028.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Daniela Jodorkovsky
    • 1
  • Yuki Young
    • 1
  • Maria T. Abreu
    • 1
    • 2
  1. 1.Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease CenterMount Sinai School of MedicineNew YorkUSA
  2. 2.Division of GastroenterologyUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations